Riboflavin biosynthesis and utilization in Mycobacterium tuberculosis

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Jessica Chuang Seeliger
Organization: STATE UNIVERSITY NEW YORK STONY BROOK
Fiscal Year: 2024
Award: $239,250
Funding agency: National Institute of Allergy and Infectious Diseases

SUMMARY
 The search for more effective treatment and prevention of tuberculosis has motivated the identification
genes that are essential for the growth and survival of the causative agent, Mycobacterium tuberculosis (Mtb).
These genes are potential new targets for developing and attenuated live vaccines. For example, targeting
metabolite biosynthesis can prevent Mtb from making essential building blocks and generate auxotrophs that
induce protective immunity, but do not cause disease. Riboflavin (vitamin B2) biosynthesis has been proposed
as a drug target because putative biosynthetic genes have been shown as essential in multiple transposon
screens, but Mtb is assumed to be unattainable as a riboflavin auxotroph and depend entirely on de novo
synthesis in vivo because it lacks a homologue for a known bacterial riboflavin transporter. However, our
critical review of the literature along with our preliminary data on inducible knockdown strains for riboflavin
biosynthesis genes provide an opportunity to test our central hypothesis that Mtb takes up riboflavin via a
noncanonical transport mechanism. We will test this hypothesis by identifying metabolites and genes that
support Mtb growth when riboflavin biosynthesis is disrupted and determining whether riboflavin metabolites
are limiting for Mtb growth in the host. If our hypotheses are correct, we expect to identify novel aspects of Mtb
metabolite uptake and utilization and determine the feasibility of target riboflavin biosynthesis as drug targets in
vivo, with potential impcats for the study of metabolite transporters in other intracellular pathogens.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Aerosols><Affect><Anabolism><Antibiotic Resistance><Antigens><Antitubercular Agents><Assay><Attenuated Vaccines><Basic Research><Basic Science><Bioassay><Biological Assay><COVID-19 virus><COVID19 virus><CRISPR interference><CRISPR-dCas9-mediated repression><CRISPR/dCas9 interference><CRISPR/dCas9-mediated transcriptional inhibition><CRISPRi><Cause of Death><Clustered Regularly Interspaced Short Palindromic Repeats interference><CoV-2><CoV2><Communicable Diseases><Data><Disease><Disease Progression><Disorder><Drug Targeting><Gene Expression><GeneHomolog><Generalized Growth><Generations><Genes><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genus Mycobacterium><Growth><Histopathology><Homolog><Homologous Gene><Homologue><Immune response><Immunity><Immunological response><In Vitro><Infection><Infectious Agent><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Intermediary Metabolism><Knowledge><Libraries><Live-attenuated Vaccine><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Measures><Metabolic Processes><Metabolism><Mission><Mucosa><Mucosal Tissue><Mucous Membrane><Mycobacterium><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><National Institute of Allergy and Infectious Disease><Organism><Pathway interactions><Prevention><Public Health><Recombinant DNA Technology><Research><Resistance to antibiotics><Resistant to antibiotics><Review Literature><Riboflavin><Ribs><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Supplementation><T-Cells><T-Lymphocyte><TB infection><TB therapy><TB treatment><Testing><Time><Tissue Growth><Tuberculosis><Tuberculostatic Agents><Vaccines><Vitamin B 2><Vitamin B2><Vitamin G><Work><Wuhan coronavirus><anti-TB><anti-tuberculosis><antiTB><antibiotic drug resistance><antibiotic resistant><biosynthesis><coronavirus disease 2019 virus><coronavirus disease-19 virus><disseminated TB><disseminated tuberculosis><effective therapy><effective treatment><enzyme biosynthesis><genetically engineered><hCoV19><host response><human pathogen><immune system response><immunogen><immunogenicity><immunoresponse><improved><in vivo><infection due to Mycobacterium tuberculosis><infectious organism><knock-down><knockdown><live vaccine><live vaccines><living system><mouse model><mtb><murine model><mutant><mycobacterial><nCoV2><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ontogeny><pathogen><pathway><prevent><preventing><repressing CRISPR-dCas9 system><rib bone structure><thymus derived lymphocyte><treat M. tuberculosis><treat Mtb><treat Mycobacterium tuberculosis><treat tb><treat tuberculosis><tuberculosis infection><tuberculosis therapy><tuberculosis treatment><tuberculous spondyloarthropathy><uptake>